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Abstract
Background and objectives Intravenous iron therapy for chronic anemia management is largely driven by
dosing protocols that differ in intensity with respect to dosing approach (i.e., dose, frequency, and duration).
Little is known about the safety of these protocols.
Design, setting, participants, & measurements Using clinical data from a large United States dialysis provider
linked tohealth careutilizationdata fromMedicare,weconstructedacohort ofpatientswithESKDaged$65years
who initiated and continued center-based hemodialysis for$90 days between 2009 and 2012, and initiated at least
one of the five common intravenous iron administration strategies; ranked by intensity (the amount of iron given
at moderate-to-high iron indices), the order of strategies was 3 (least intensive), 2 (less intensive), 1 (reference),
4 (more intensive), and 5 (most intensive). We estimated the effect of continuous exposure to these strategies
on cumulative risks of mortality and infection-related events with dynamic Cox marginal structural models.
Results Of 13,249 eligible patients, 1320 (10%) died and 1627 (12%) had one or more infection-related events
during the 4-month follow-up. Themost and least commonly initiated strategywas strategy 2 and 5, respectively.
Comparedwith the reference strategy 1,more intensive strategies (4 and 5) demonstrated ahigher risk of all-cause
mortality (e.g., most intensive strategy 5: 60-day risk difference: 1.3%; 95% confidence interval [95% CI], 0.8%
to 2.1%; 120-day risk difference: 3.1%; 95% CI, 1.0% to 5.6%). Similarly, higher risks were observed for
infection-related morbidity and mortality among more intensive strategies (e.g., strategy 5: 60-day risk
difference: 1.8%; 95% CI, 1.2% to 2.6%; 120-day risk difference: 4.3%; 95% CI, 2.2% to 6.8%). Less intensive
strategies (2 and 3) demonstrated lower risks of all-cause mortality and infection-related events.
Conclusions Among dialysis patients surviving 90 days, subsequent intravenous iron administration
strategies promoting more intensive iron treatment at moderate-to-high iron indices levels are associated
with higher risks of mortality and infection-related events.
Clin J Am Soc Nephrol 14: 728–737, 2019. doi: https://doi.org/10.2215/CJN.03970318
Introduction
Intravenous (IV) iron is either provided via large doses
over consecutive hemodialysis sessions (often
termed “bolus dosing”) or via small doses provided
every 1–2 weeks (often termed “maintenance dos-
ing”) for anemia management in contemporary clin-
ical practice. Decisions about the exact sequence
of iron administration are typically guided by iron
indices levels—serum ferritin and transferrin satura-
tion (TSAT)—and hemoglobin (1,2). On the basis of
these tests, providers make recommendations about
the dosing approach (i.e., bolus dosing, maintenance
dosing, or another variation) for the next treatment
course.
Currently, dialysis clinics rely on dosing protocols
that prescribe dosing approaches for IV iron admin-
istration. These protocols factor in a patient’s iron
indices levels and evolving clinical characteristics to
provide treatment recommendations with the primary
goal of achieving a target hemoglobin level while
not exceeding the upper limits of ferritin and TSAT.
Consequently, the treatment dose, frequency, and
duration (dosing approach) are repeatedly adjusted
when updated iron indices and clinical characteristics
become available. These dosing protocols are known
as dynamic administration strategies (3–5).
Surprising variation exists in protocols used in
clinical practice, perhaps reflective of the lack of
consensus among expert guidelines (1,2,6–9). These
protocols differ in intensity with respect to target levels
of iron indices and dosing approach recommendations
(10–12). For example, one protocol may specify 100 mg
of iron administered over ten consecutive dialysis
sessions for TSAT,30% and ferritin ,1200 ng/ml,
whereas another protocol would hold iron for any
ferritin .500 ng/ml regardless of TSAT level.
Although previous studies have examined the
safety of IV iron, none have formally assessed dosing
protocols (13,14). Existing observational studies
(15–17) have largely focused on the effect of cumula-
tive iron exposure over a long period that may over-

































IV iron administration strategy in the index treatment
interval anchored by the index TSAT and its subsequent
TSAT. We defined the baseline period as the period starting
90 days before dialysis initiation and ending on the day
before the index date. Eligible patients were followed for
outcomes of interest in a 4-month follow-up period, starting
on day 15 (the day after the index strategy assessment
window) (Figure 1).
Our study population comprised outpatients who initi-
ated in-center hemodialysis between January 1, 2009 and
September 16, 2012 and survived 90 days after initiation
(Supplemental Figure 1). We excluded patients who (1)
were aged ,65 years at initiation (to ensure the collection
of their comprehensive clinical history for confounding
control), (2) did not have Medicare as primary insurer, (3)
did not continue hemodialysis for $90 days, (4) had
incomplete baseline covariates information (24), or (5)
had fewer than nine dialysis sessions in the month pre-
ceding the index date to ensure they were receiving regular
hemodialysis and anemia management. We also excluded
patients with polycystic kidney disease because their iron
administration strategies could differ because of their
heterogeneous need for erythropoiesis stimulating agents.
IV Iron Administration Strategies
We considered five dynamic IV iron administration
strategies that were adapted from existing protocols used
by several dialysis organizations in contemporary routine
practice. Each strategy consisted of a set of decision rules
that specified a range of acceptable iron therapy values
during a treatment course given a patient’s current iron
indices (Tables 1 and 2). Ranked by intensity of iron
treatment, the amount of iron given at moderate-to-high
iron indices, the order of strategies was 3 (least intensive),
2 (less intensive), 1 (reference), 4 (more intensive), and
5 (most intensive).
We identified the IV iron administration strategies
initiated by eligible patients in the index treatment
interval by matching a patient’s treatment pattern in
the 14-day assessment window and current iron indices
values with candidate strategies by concordance (23). The
length of assessment window was chosen to maximize
the representativeness of treatment experience in the
assessment window for the treatment experience during
the entire treatment course as well as minimizing the
days required for assessment to maximize follow-up time
for outcomes (Supplemental Figure 2). Patients were
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Figure 1. | Study design for assessing the effect of initiating and staying on a particular dynamic IV iron administration strategy. Patients are
followed startingon theendof thefirst 14-day iron strategyassessmentwindow(thegrayblock) for all-causemortalityor infection-relatedevents.
Those deviated from their index strategy are censored at the end of current assessment window.
trajectories (18). Cumulative iron exposures may also not 
align well with the treatment decisions that providers make 
regarding iron administration in clinical practice (19). Ran-
domized, clinical trials assessing multiple dosing protocols 
are lacking. As such, the risks of infectious complications and 
mortality are unclear given conflicting conclusions of existing 
studies (12–17,20,21) and the insufficiency of the current 
literature on safety of dosing protocols.
Given the high prevalence of IV iron (22), we conducted a 
study to examine the effect of continues treatment with five 
commonly used dynamic IV iron administration strategies on 
risks of all-cause mortality and infection-related events in a 
contemporary cohort of patients on hemodialysis.
Materials and Methods
Data Sources
We constructed a large hemodialysis patient cohort using 
deidentified datasets derived from the electronic health 
records of a large dialysis organization in the United States, 
linked with the US Renal Data System (USRDS). We obtained 
detailed clinical information regarding patients’ dialysis treat-
ments, vascular access, laboratory test data, IV medications, 
and anemia management using the clinical database from the 
dialysis organization. We obtained information regarding 
their demographics, comorbidities, health care system en-
counters, and outcomes from the USRDS. The study was 
approved by the Institutional Review Board at University of 
North Carolina at Chapel Hill (approval  no. 15–1991).
Study Design and Study Population
Detailed methods for cohort construction have been 
described elsewhere (23). Briefly, we used a retrospective 
cohort design with the index date for IV iron administra-
tion strategy defined as the day of the first TSAT test result 
within 90–136 days after dialysis initiation to ensure 
patients were receiving chronic anemia management. We 
anchored the index date on a TSAT measurement because 
in clinical practice: (1) decisions about subsequent IV iron 
dosing approach typically occur upon the availability of 
iron indices tests; (2) TSAT is updated slightly more 
frequently than ferritin (approximately monthly versus 
quarterly); and (3) when no current ferritin test is available, 
the last available ferritin is used with the updated TSAT to 
make treatment recommendations. The TSAT measurement 
on the index date was defined as the index TSAT. We used 
the 14-day window after the index TSAT to assess the index
excluded from the main analyses if their treatment
patterns in the assessment window were incompatible
with all candidate strategies.
Effect Measure of Interest
We estimated the 120-day cumulative risks of all-cause
mortality and infection-related events under continuous
treatment with each IV iron administration strategy. We
focused on this per-protocol effect of these administration
strategies—the effect that would have been observed if
patients had adhered to their assigned strategy throughout
the 120-day follow-up—because the typical intention-to-
treat effect may be suboptimal for assessment of
comparative safety, particularly in the presence of non-
adherence to the strategy (25,26).
Outcomes
Two safety outcomes examined were all-cause mortality
and a composite outcome of infection-related hospitaliza-
tion (sepsis, vascular access infection, or pneumonia) or
death in the 4 months after initiation of IV iron adminis-
tration strategy. These events were identified using claims-
based definitions (Supplemental Table 1).
Patients were censored by death attributed to reasons other
than infection (for the infection-related events outcome),
receipt of kidney transplantation, time of switchingmodality,
loss to follow-up, disenrollment from the dialysis provider,
loss of Medicare coverage, or the administrative end of
follow-up (December 31, 2012). For both analyses, patients
were also censored by deviation from index strategy when
they received treatment in away inconsistentwith their index
strategy (Supplemental Material, Supplemental Figure 3).
Covariates
Covariates (defined in Supplemental Table 2) in the
analyses included demographic characteristics (e.g., age,
sex, race, year of strategy initiation), clinical characteristics
(e.g., cause of ESKD, body mass index), baseline anemia
treatment history (IV iron and epoetin dose), facility-related
factors (geographical region of dialysis clinic, vascular
access type), parameters reflective of anemia management
(e.g., TSAT, ferritin, epoetin dose, hemoglobin, receipt of blood
transfusion), parameters reflective of inflammation (albumin,
creatinine, systolic BP, postdialysis body weight), health
care system encounters (e.g., number of dialysis sessions,
days of hospitalization), and a list of comorbidities.
Table 1. Definitions of dynamic intravenous iron administration strategies
Strategy Definitions TSAT, % Ferritin, ng/ml
Strategy 1
,200 200–1200 .1200
,20 Bolus Low maintenance None
20–50 Maintenance Low maintenance None
.50 None None None
Strategy 2
,200 200–800 .800
,20 Bolus Low maintenance None
20–50 Maintenance Low maintenance None
.50 None None None
Strategy 3
,200 200–500 .500
,20 Bolus Low maintenance None
20–50 Maintenance Low maintenance None
.50 None None None
Strategy 4
,800 800–1200 .1200
,30 Bolus Half bolus None
30–50 Low maintenance Low maintenance None




30–40 Half bolus None
41–49 Maintenance None
$50 None None




Bolus .500 100 mg3ten consecutive
sessions
Half bolus 201–500 100 mg3five consecutive
sessions
Maintenance 101–200 100 mg weekly
Low maintenance 1–100 25 or 50 mg weekly
None 0 0 mg
aThedosingapproachpresentedwason thebasisof ironsucrose.
For other intravenous iron formulations, their monthly equiv-
alencewasused.Forexample, for thebolusdosingapproach, the
monthly iron dosage level was 1000 mg in one dialysis session
with iron dextran, and 125 mg over eight consecutive dialysis
sessions with ferric gluconate.
catheter. Recent history of infections and comorbidities
were more common among the most intensive strategy
5 initiators, who were also more likely to have had a
gastrointestinal bleed or received blood transfusion. Dur-
ing the last baseline month, they received higher doses of
epoetin and IV iron and spent more days in the hospital.
Their index TSAT and ferritin levels were also higher.
During follow-up, patients deviated from their index
strategy quickly, especially among initiators of more in-
tensive strategies 4 and 5 (Supplemental Figure 4). The
median time to deviation was shortest among strategy 5
and longest in strategy 2 (49 versus 131 days). By the end of
4 months, 40%–80% of patients had deviated from their
index strategies. Factors that increased the probability of
deviation included vascular access-related infection in the
last baseline month, use of a catheter, higher albumin level,
fewer dialysis sessions, and higher epoetin doses in the
previous treatment interval. In contrast, having blood trans-
fusions and longer hospital stays in the previous treatment
interval reduced the probability of deviation.
During the first 4 months of follow-up, 1320 (10%)
patients died and 1627 (12%) patients had at least one
infection-related events. The unadjusted RDs of all-cause
mortality and infection-related risks comparing each strat-
egy with referent strategy 1 during the 4-month follow-up
are shown in Supplemental Figures 5 and 6.
Figure 2 presents the estimated cumulative RDs of all-cause
mortality among strategy groups in the first 4 months,
adjusted for baseline confounding and strategy deviation in
the follow-up. Compared with strategy 1, initiators of less
intensive strategies (2 and 3) had lower but nonstatistically
significant mortality risks; initiators of more intensive strat-
egy 4 had higher risks, and the adjusted RDs and 95% CIs
at 2 and 4 months were 0.6% (95% CI, 0.3% to 1.1%) and
1.5% (95% CI, 0.1% to 3.1%), respectively. The crude
estimates were 1.0% and 1.7%, respectively. The highest
risks were among initiators of the most intensive strategy
5, and RDs at 2 and 4 months were 1.3% (95% CI, 0.8% to
2.1%) and 3.1% (95% CI, 1.0% to 5.6%), respectively. Their
respective crude estimates were 2.5% and 3.4%.
A similar trendwas observed for the composite outcome of
infection-related events in the 4months (Figure 3). Compared
with strategy 1, initiators of more intensive strategies (4 and
5) had higher risks, whereas those of less intensive strategies
(2 and 3) had little difference. At 2 months, RDs for more
intensive strategies (4 and 5) were 0.8% (95% CI, 0.3% to
1.3%) and 1.8% (95% CI, 1.2% to 2.6%), respectively. At
4 months, their respective RDs increased to 1.7% (95% CI,
0.4% to 2.9%) and 4.3 (95% CI, 2.2% to 6.8%).
We conducted sensitivity analyses varying the definition
for strategy deviation, and our results were robust to such
changes. We also examined censoring models with differ-
ent sets of covariates to adjust for strategy deviation, and
the results were robust to the variations in the models.
Little difference was seen among the estimates except for
the intercept-only model with no covariate (Supplemental
Figures 7 and 8).
Discussion
In a large cohort of older patients on hemodialysis,
we assessed the effect of continuous use of five common
Statistical Analyses
We compared IV iron administration strategies with re-
spect to risks of all-cause mortality and infection-related 
events using inverse probability weighted estimation of Cox 
marginal structural models (27,28). We chose strategy 1 as the 
reference because of its frequent use and ranked intensity 
among the five strategies (Table 1). Standardized mortality 
ratio weighting (29) was used to adjust for potential baseline 
confounding. As a multivariable standardization method, 
this weighting method uses the treated study participants 
(i.e., the patients who initiated strategy 1 in this analysis) as 
the standard population and estimates the treatment effect 
in a population whose distribution of risk factors is equal to 
that of the treated study participants. Inverse probability of 
censoring weighting (30) was used to adjust for potential 
selection bias introduced by censoring patients who deviated 
from index strategies in the follow-up. The model for 
censoring weights included time-dependent factors for both 
outcomes and strategy deviation (including length of hospital 
stay, total epoetin doses, number of dialysis sessions, vascular 
access type, and current iron indices in the treatment course 
before deviation), and time-independent factors (including 
sex, cause of ESKD, and comorbidities). We estimated 
cumulative risk differences (RDs) for both mortality and 
infection-related outcomes comparing each strategy with 
the referent strategy 1 during follow-up, and their 95%
confidence intervals (95% CIs) using a nonparametric 
bootstrap procedure with 200 repetitions (31).
We conducted sensitivity analyses using different co-
variates for censoring weights estimation and various 
definitions for strategy deviation. We also conducted 
additional analyses to estimate different effects of strat-
egy exposure. These analyses were described more 
completely in Supplemental Material. All statistical anal-
yses were performed using R 3.3.1 (R Foundation for 
Statistical Computing, Vienna, Austria) and SAS 9.4 (SAS 
Institute Inc., Cary, NC).
Results
Between 2009 and 2012, 18,697 patients met our study 
entry criteria (Supplemental Figure 1), and 15,518 (83%) 
patients were matched with at least one IV iron adminis-
tration strategy under consideration. Among them, 13,249 
(71%) patients initiated one of the five most commonly 
used strategies and were included in the analyses. At 
strategy initiation, the average age was 76 years. About half 
of the cohort were women, and 23% were black. The most 
and least commonly initiated strategy was strategy 2 and 5, 
respectively. More intensive strategies 4 and 5 recom-
mended more aggressive iron therapy in broader ranges of 
TSAT and ferritin. For example, strategy 5 recommended 
bolus dosing if TSAT,30% and ferritin ,1200 ng/ml, half 
bolus dosing if TSAT was between 30% and 40%, and 
maintenance dosing if TSAT was between 40% and 50%. 
Definitions of the strategies and dosing approaches are
listed in Tables 1 and 2.
Table 3 presents patients’ baseline characteristics strat-
ified by strategy. Baseline characteristics were similar 
among initiators of strategies 1, 2, and 3. Compared with 
these patients, initiators of more intensive strategies (4 and 
5) were more likely to initiate in early years and used a
Table 3. Baseline characteristics of patients on hemodialysis by initiated IV iron administration strategy, 2009–2012
Characteristics Overall Strategy 1 Strategy 2 Strategy 3 Strategy 4 Strategy 5
N 13,249 10,882 11,293 10,397 8089 6305
Age, mean (SD) 76 (7) 76 (7) 76 (7) 76 (7) 76 (7) 76 (7)
Women, % 49 49 50 49 49 49
Race, %
Black 23 22 23 22 22 22
White 72 73 72 73 73 73
Other 5 5 5 5 5 5
Medicaid, % 29 29 29 29 29 30
Lower income subsidy, % 34 34 34 34 35 35
Region, %
Midwest 23 23 23 23 23 23
Northeast 14 14 14 14 14 14
Other 0.0 0.0 0.0 0.0 0.0 0.0
South 42 41 42 42 43 43
West 21 21 21 21 20 20
Cause of ESKD, %
Diabetes 45 45 45 45 45 44
GN 5 5 5 5 5 5
Hypertension 36 36 36 36 36 36
Other 13 14 14 14 14 15
Missing 0.3 0.4 0.4 0.4 0.4 0.4
Index year, %
2009 25 23 24 25 27 29
2010 25 23 23 25 26 28
2011 25 27 27 26 24 22
2012 25 27 26 23 23 21
Comorbidities, %
Vascular access infectiona 1 1 1 1 2 2
Pneumoniaa 2 2 2 2 3 3
Sepsisa 2 3 2 3 3 4
Infection (ADR definition)a 4 4 4 4 5 6
Antibiotic usea 20 21 21 21 24 28
IV antibiotics (dialysis center)a 11 12 12 12 14 17
Infection (broad definition)a 24 26 26 26 29 34
Diabetes 69 70 69 70 69 70
Hypertensive disease 96 95 95 96 96 97
Congestive heart failure 62 62 63 63 64 66
Myocardial infarction, acute 10 10 10 10 10 10
Angina 7 7 7 7 7 7
Coronary artery
disease/atherosclerosis
56 56 56 57 58 59
Ischemic stroke 8 8 8 8 8 9
Intracerebral hemorrhage 0.3 0.3 0.3 0.3 0.3 0.3
Subarachnoid hemorrhage 0.1 0.1 0.1 0.1 0.1 0.1
Hemorrhagic stroke 0.7 0.7 0.7 0.7 0.8 0.8
Cerebrovascular disease 24 24 24 24 24 25
Chronic obstructive pulmonary
disease and asthma
33 33 33 34 34 36
Hyperlipidemia 61 60 60 61 60 60
Cancer 21 22 22 22 22 23
Liver disease 4 4 4 4 4 5
Gastrointestinal bleeding and ulcer 3 3 3 3 3 3
Blood transfusion 36 36 36 37 38 41
Blood loss anemia 5 5 5 5 6 6
Peripheral vascular disease 26 27 27 27 27 28
Rheumatic heart disease 6 6 6 6 6 7
Psychiatric disorder 6 6 6 6 6 7
Substance abuse 6 6 6 7 7 7
Autoimmune disorder 5 5 5 5 5 5
Other neurologic disorders 14 14 14 14 15 16
Hyperparathyroidism 4 4 4 4 4 4
Chronic heart disease procedures 6 5 6 6 5 6
Rheumatoid arthritis 3 3 3 3 3 3
Neuropathy 21 21 21 21 21 22
Osteoarthritis 20 20 20 20 20 21
Osteoporosis 5 5 5 5 5 5
History of fall 5 6 5 5 6 6
Last month of baseline period, mean (SD)b
Total EPO dose, 1000 units/mo 68 (73) 68 (73) 68 (73) 71 (75) 73 (79) 83 (83)
Total iron dose, mg 299 (311) 293 (296) 288 (299) 289 (308) 310 (322) 334 (343)
IV iron administration strategies for chronic anemia
management on risks of mortality and infection-related
events. Higher risks were observed among users of
strategies that adopted more intensive dosing approaches
(4 and 5) at higher levels of iron indices. Compared with
strategy 1, the most intensive strategy 5 may result in an
additional 13 deaths (95% CI, 8 to 21) or 18 infection-related
events (95% CI, 12 to 26) per 2 months per 1000 patients
treated. Higher risks were also observed with more
intensive strategy 4 but with a smaller magnitude.
Although previous studies, included in a recently
published meta-analysis (13), have examined safety of
Table 3. (Continued)
Characteristics Overall Strategy 1 Strategy 2 Strategy 3 Strategy 4 Strategy 5
TSAT, % 25 (12) 25 (12) 25 (13) 25 (13) 25 (13) 25 (14)
Ferritin, ng/ml 490 (435) 471 (437) 487 (446) 484 (463) 488 (482) 511 (525)
Hemoglobin, g/dl 11.5 (1.4) 11.4 (1.4) 11.5 (1.4) 11.5 (1.5) 11.5 (1.5) 11.4 (1.5)
Albumin, g/dl 3.6 (0.5) 3.6 (0.5) 3.6 (0.5) 3.6 (0.5) 3.6 (0.5) 3.5 (0.5)
Creatinine, mg/dl 5.1 (1.9) 5.1 (1.9) 5.1 (1.9) 5.1 (1.9) 5.1 (1.9) 5.0 (1.9)
Pretreatment systolic BP, mm Hg 143 (22) 143 (22) 143 (22) 143 (22) 142 (22) 142 (22)
Post-treatment weight, kg 74 (18) 75 (19) 75 (19) 75 (19) 75 (19) 74 (19)
Hospital days 0.7 (2.0) 0.8 (2.0) 0.7 (2.0) 0.8 (2.1) 0.9 (2.2) 1.0 (2.3)
No. of transfusions 0.03 (0.20) 0.03 (0.22) 0.03 (0.21) 0.03 (0.22) 0.04 (0.25) 0.05 (0.27)
Access, %
Catheter 63 63 64 65 66 70
Fistula 27 26 26 25 24 21
Graft 11 10 10 10 10 9
Index date, mean (SD)c
Index TSAT, % 28 (14) 29 (14) 29 (14) 29 (15) 31 (16) 29 (18)
Index ferritin, ng/ml 546 (464) 526 (488) 543 (487) 536 (506) 560 (549) 584 (608)
Index hemoglobin, g/dl 11.6 (1.3) 11.5 (1.3) 11.5 (1.3) 11.6 (1.3) 11.6 (1.4) 11.5 (1.4)
Index albumin, g/dl 3.6 (0.5) 3.6 (0.5) 3.6 (0.5) 3.6 (0.5) 3.6 (0.5) 3.5 (0.5)
Index creatine, mg/dl 5.2 (2.0) 5.2 (2.0) 5.2 (2.0) 5.2 (2.0) 5.2 (2.0) 5.2 (2.0)
IV, intravenous; ADR, annual data report; EPO, epoetin; TSAT, transferrin saturation.
aPrevalence during the last month of baseline period.
bIf a laboratory test in the last month of baseline was missing, the previous test value was used.
cIf a laboratory test was missing on the index date, the last nonmissing test value was used.
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Figure 2. | After adjustment for baseline confounding and strategy deviation in the follow-up, higher cumulative risks of all-cause mortality
wereassociatedwithmore intensestrategiescomparedwith thereferencestrategy1 in the4-month follow-up.TheseRDs representdifferences
in risks of all-causemortality if strategy 1 users, contrary to fact, initiated and stayed on another intravenous iron strategy instead of initiating and
staying on strategy 1 during the 120-day follow-up.
cumulative doses of IV iron, to our knowledge, this study is
the first to assess the safety profile of IV iron administration
strategies reflective of clinical practice among patients on
hemodialysis. To approximate the dynamic treatment de-
cision process, we aligned exposure assessment with points
of treatment decisions (19) and compared the multidimen-
sional strategies adapted from complex protocols actually
used by dialysis organizations in contemporary clinical
practice.
Ideally, we could answer questions about the comparative
safety and efficacy of different strategies with randomized,
clinical trials. However, trials assessing multiple strate-
gies are currently lacking and may be infeasible in
many cases because of cost, time, and ethical constraints.
The recent published Proactive IV irOn Therapy in
haemodiALysis Patients (PIVOTAL) trial examined two
strategies that were less intensive than all five strategies in
this study: a proactive regimen administering 400 mg of iron
sucrose monthly (equivalent of maintenance dosing) to
ferritin #700 ng/ml or TSAT,40%, and a reactive regimen
administering a monthly dose of 0–400 mg of iron sucrose to
maintain ferritin at 200 ng/ml and TSAT at 20% (32). By
examining five commonly used strategies in the United States
at the same time, our study could augment the trial with
information on safety of more intensive IV iron dosing
strategies.
Our findings that intensive strategies had higher infec-
tion risks seemingly contrast with the PIVOTAL trial that
found no difference in infection risks between the proactive
and reactive regimens (32). The difference might be
explained by the different intensity of iron therapy among
the strategies examined in the trial and this study. Patients
in the proactive regimen in the trial received a median
monthly dose of 264 mg (and a maximum of 400 mg),
which is lower than the median amount received by
patients of all five strategies in this study and also the
current practice patterns for bolus or “half-bolus” dosing.
Additionally, the trial included incident patients on hemo-
dialysis whomay have a different safety profile from patients
with longer dialysis vintage and more complex comorbid-
ities included in this study.
Our findings confirm and complement findings from
prior observational studies. One cohort study observed
higher risk of infection-related events with bolus dosing
approach compared with maintenance dosing (21). Yet the
magnitude of current results was larger, which might be
attributable to the difference in strategy definition and age
of study population. Another cohort study also showed
higher mortality risk associated with nonmaintenance
over maintenance strategies (12). They defined mainte-
nance strategy as having IV iron in a regular schedule and
nonmaintenance strategy as having any other adminis-
tration practices, which included patients that had spo-
radic or no use. Hence, no direct comparisons could be
drawn because of the substantially different strategy def-
initions.
Among these strategies in our study, the main difference
was the ferritin level at which iron treatment should be
withheld. The findings suggest that aggressive iron treat-
ment with moderate-to-high ferritin level could contribute
to increased risks. Compared with strategy 1 that stopped
iron at ferritin of 1200 ng/ml, less intensive strategies
2 and 3 that had same TSAT levels indicating a particular
dosing approach but lower stopping ferritin levels (800 and
500 ng/ml, respectively) had modestly lower all-cause









120-day RD (95% CI), %














Figure 3. | After adjustment for baseline confounding and strategy deviation in the follow-up, higher cumulative risks of infection-related
events were associated with more intense strategies compared with the reference strategy 1 in the 4-month follow-up. These RDs represent
differences in risks of infection-related events if strategy 1users, contrary to fact, initiated and stayedonanother intravenous iron strategy instead
of initiating and staying on strategy 1 during the 120-day follow-up.
strategy deviation and outcomes of interest, adjustment
of which would potentially attenuate the effect. How-
ever, we adjusted for an extensive list of clinical,
laboratory, treatment, and demographic variables and
achieved good balance in the distribution of these
covariates after weighting. Sensitivity analyses examin-
ing different sets of covariates for the censoring model
showed the results were robust to changes in the models,
suggesting the possibility that the association between
strategy deviation and the outcomes under study might
not be strongly confounded by the measured covariates.
We may have missed or misclassified comorbidities
because they were ascertained only if coded claims are
available in the USRDS. Furthermore, we only included
limited facility-specific variables, which may not fully
account for facility effect associated with iron use and
outcomes of interest.
In conclusion, there remains variation in the guidelines
for IV iron administration among patients on hemodial-
ysis. We found that strategies recommending relatively
aggressive IV iron supplementation, especially at the
moderate-to-high levels of ferritin and TSAT, were
associated with higher risks of all-cause mortality and
infection-related events. Our findings suggest caution for
intense IV iron administration among older patients with
elevated ferritin levels.
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Compared with strategy 1, strategies 4 and 5 that made 
more intensive treatment recommendations at moderate-
to-high levels of iron indices had higher risks of adverse 
events. The higher risks could potentially be explained 
by iron overload with persistent administration of IV 
iron in the setting of relatively high ferritin levels and 
were consistent with previous studies (22,33,34) and the 
anticipated adverse effects of excessive use of IV iron in 
this vulnerable population (35). These results suggest 
that the role and cutoff values of ferritin level should be 
thoroughly examined in determining IV iron dosing.
We focused on the per-protocol effect of these dynamic 
administration strategies using a “cloning and censoring” 
approach (27). With this approach, multiple strategies could 
be assigned to a single patient if the treatment patterns were 
consistent. This approach has been widely used for the 
estimation of per-protocol effect (36–39). However, with this 
approach, an intention-to-treat analysis, i.e., comparing the 
initial strategy, would not be informative, especially when 
considering dynamic treatment strategies that have overlapping 
regions and many patients may have been assigned to many or 
even all strategies (26).
The results of our study may not be generalizable to 
other patient populations different from those included in 
the analysis, who were aged 65 or older at dialysis initiation 
and have survived the first 90 days  of dialysis.  Compared  
with the general dialysis population, our study population 
was older and had higher proportion of male and white 
patients. Updated analyses are needed to evaluate more 
recent dosing protocols because anemia management may 
have changed, especially with the recent policy changes 
including the capitated reimbursement program. Also, 
exposure misclassification might occur in the classifica-
tion of strategies using treatment experience in a 14-day 
assessment window. However, sensitivity analyses vary-
ing the length of assessment window showed the 14-day 
window was the most representative of the treatment 
experience in the entire treatment course while maximiz-
ing time for follow-up (Supplemental Figure 2). Addi-
tionally, we applied this identification approach in 
patients on hemodialysis in a longer time period and 
found the prevalence of match between strategies and 
treatment experience increased sharply, starting in 2010 to 
91% in 2012 (23). The increasing trend of matches across 
time was consistent with the fact that the installation of 
administration strategies in dialysis clinics occurred in 
recent years. Moreover, we used ranges of iron dose to 
classify dosing approach, assuming identical treatment 
effect across the range for a single dosing approach. This 
assumption might be violated if treatment effect varies 
substantially across a range, which is unlikely as the ranges 
were narrow. Furthermore, we did not evaluate the safety 
profile by iron formulation.
Our analyses were subject to possible bias from residual 
confounding. Residual confounding by indication could 
occur if initiators of more aggressive strategies were 
inherently different and were treated more aggressively 
for some indication that we had no information on. If such 
unmeasured indication was also a risk factor for death or 
infection-related events, then the observed effects would 
be subject to bias. Similarly, residual selection bias would 
occur if there were unmeasured risk factors for both
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